Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by Wall Street Zen

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

TEVA has been the subject of several other research reports. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Scotiabank initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price objective on the stock. UBS Group boosted their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Barclays assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Buy” and a consensus target price of $30.25.

Teva Pharmaceutical Industries Trading Down 1.3%

Shares of TEVA stock opened at $29.80 on Friday. The company has a market cap of $34.18 billion, a P/E ratio of 49.67, a PEG ratio of 1.77 and a beta of 0.66. The stock has a 50 day simple moving average of $23.43 and a two-hundred day simple moving average of $19.63. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $30.20.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares in the company, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 532,360 shares of company stock valued at $14,364,929. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in TEVA. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $41,000. Cromwell Holdings LLC lifted its holdings in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after acquiring an additional 629 shares during the period. Sound Income Strategies LLC boosted its position in Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter. MAI Capital Management grew its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. Finally, Rothschild Investment LLC increased its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.